Trials / Completed
CompletedNCT01078415
Pilot Study of Irreversible Electroporation (IRE) to Treat Early-Stage Primary Liver Cancer (HCC)
A Prospective, Multi-Center, Clinical Trial Using Irreversible Electroporation (IRE) for the Treatment of Early-Stage Hepatocellular Carcinoma (HCC)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Angiodynamics, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of the NanoKnife LEDC System for the treatment of early-stage hepatocellular carcinoma (HCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Ablation with the NanoKnife Low Energy Direct Current (LEDC) System | 90 pulses of 70 microseconds each in duration will be administered per electrode pair. |
Timeline
- Start date
- 2010-02-01
- Primary completion
- 2013-01-01
- Completion
- 2013-06-01
- First posted
- 2010-03-02
- Last updated
- 2016-11-08
Locations
6 sites across 4 countries: France, Germany, Italy, Spain
Source: ClinicalTrials.gov record NCT01078415. Inclusion in this directory is not an endorsement.